Equities research analysts forecast that Sangamo Therapeutics Inc (NASDAQ:SGMO) will report earnings per share (EPS) of ($0.31) for the current quarter, according to Zacks. Four analysts have provided estimates for Sangamo Therapeutics’ earnings. The lowest EPS estimate is ($0.42) and the highest is ($0.27). Sangamo Therapeutics posted earnings of ($0.18) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 72.2%. The business is scheduled to announce its next quarterly earnings results on Thursday, February 27th.
On average, analysts expect that Sangamo Therapeutics will report full year earnings of ($1.20) per share for the current year, with EPS estimates ranging from ($1.32) to ($1.15). For the next year, analysts expect that the business will report earnings of ($1.13) per share, with EPS estimates ranging from ($1.54) to $0.10. Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that cover Sangamo Therapeutics.
Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.34) by $0.10. Sangamo Therapeutics had a negative return on equity of 30.33% and a negative net margin of 159.12%. The firm had revenue of $21.96 million during the quarter, compared to analyst estimates of $12.16 million. During the same period last year, the company posted ($0.13) EPS. The business’s quarterly revenue was down 6.8% compared to the same quarter last year.
SGMO has been the subject of several research reports. Zacks Investment Research cut shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, November 16th. Wedbush reiterated a “hold” rating and issued a $11.00 price objective on shares of Sangamo Therapeutics in a research note on Tuesday, November 12th. BidaskClub upgraded shares of Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, November 28th. Finally, HC Wainwright began coverage on shares of Sangamo Therapeutics in a research report on Monday, August 26th. They issued a “buy” rating and a $16.00 target price for the company. Three research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the stock. Sangamo Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $13.50.
Several institutional investors have recently made changes to their positions in SGMO. BlackRock Inc. increased its holdings in Sangamo Therapeutics by 13.2% in the second quarter. BlackRock Inc. now owns 9,432,178 shares of the biopharmaceutical company’s stock worth $101,584,000 after buying an additional 1,098,030 shares during the last quarter. Nuveen Asset Management LLC bought a new stake in Sangamo Therapeutics during the second quarter worth approximately $8,516,000. Vanguard Group Inc. raised its position in shares of Sangamo Therapeutics by 7.7% in the second quarter. Vanguard Group Inc. now owns 8,309,161 shares of the biopharmaceutical company’s stock valued at $89,490,000 after purchasing an additional 596,573 shares during the period. Candriam Luxembourg S.C.A. bought a new position in Sangamo Therapeutics in the 2nd quarter worth $4,450,000. Finally, Macquarie Group Ltd. lifted its position in Sangamo Therapeutics by 247.8% during the 2nd quarter. Macquarie Group Ltd. now owns 400,000 shares of the biopharmaceutical company’s stock worth $4,308,000 after acquiring an additional 285,000 shares during the last quarter. Institutional investors and hedge funds own 70.78% of the company’s stock.
Shares of SGMO traded down $0.10 during trading hours on Friday, reaching $11.60. The company’s stock had a trading volume of 1,995,316 shares, compared to its average volume of 1,771,767. The company has a 50 day moving average of $9.55 and a two-hundred day moving average of $10.24. The company has a quick ratio of 4.77, a current ratio of 4.77 and a debt-to-equity ratio of 0.10. The firm has a market cap of $1.36 billion, a price-to-earnings ratio of -16.56 and a beta of 2.84. Sangamo Therapeutics has a 1-year low of $6.26 and a 1-year high of $13.91.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation.
Further Reading: Why do company’s buyback their stock?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.